Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa

I. Cass; E. Resnik; J. T. Chambers; S. K. Chambers; M. L. Carcangiu; E. I. Kohorn; P. E. Schwartz

doi:10.1006/gyno.1996.0148

Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa

I. Cass, E. Resnik, J. T. Chambers, S. K. Chambers, M. L. Carcangiu, E. I. Kohorn, P. E. Schwartz

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Eleven patients with ovarian (9) or fallopian tube (2) mixed müllerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and doxorubicin. Responses were observed in three (60%) of five evaluable patients with two complete (40%) and one partial (20%) response. Median survival time was 17 months with an estimated 3-year survival of 18%. Survival may have been improved with earlier stage disease, but survival was not significantly improved with optimal surgical cytoreduction in patients with advanced disease. Four patients required dose reductions for myelosuppression and there was one treatment related death. Toxicity was comparable to other combination chemotherapy regimens. EPA has modest therapeutic activity in ovarian and fallopian tube MMT.

Original language	English (US)
Pages (from-to)	309-314
Number of pages	6
Journal	Gynecologic oncology
Volume	61
Issue number	3
DOIs	https://doi.org/10.1006/gyno.1996.0148
State	Published - Jun 1996
Externally published	Yes

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1006/gyno.1996.0148

Cite this

@article{5d726227a9514e9b916c8e2980de21b9,

title = "Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed m{\"u}llerian tumors of the adnexa",

abstract = "Eleven patients with ovarian (9) or fallopian tube (2) mixed m{\"u}llerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and doxorubicin. Responses were observed in three (60%) of five evaluable patients with two complete (40%) and one partial (20%) response. Median survival time was 17 months with an estimated 3-year survival of 18%. Survival may have been improved with earlier stage disease, but survival was not significantly improved with optimal surgical cytoreduction in patients with advanced disease. Four patients required dose reductions for myelosuppression and there was one treatment related death. Toxicity was comparable to other combination chemotherapy regimens. EPA has modest therapeutic activity in ovarian and fallopian tube MMT.",

author = "I. Cass and E. Resnik and Chambers, {J. T.} and Chambers, {S. K.} and Carcangiu, {M. L.} and Kohorn, {E. I.} and Schwartz, {P. E.}",

year = "1996",

month = jun,

doi = "10.1006/gyno.1996.0148",

language = "English (US)",

volume = "61",

pages = "309--314",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa

AU - Cass, I.

AU - Resnik, E.

AU - Chambers, J. T.

AU - Chambers, S. K.

AU - Carcangiu, M. L.

AU - Kohorn, E. I.

AU - Schwartz, P. E.

PY - 1996/6

Y1 - 1996/6

N2 - Eleven patients with ovarian (9) or fallopian tube (2) mixed müllerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and doxorubicin. Responses were observed in three (60%) of five evaluable patients with two complete (40%) and one partial (20%) response. Median survival time was 17 months with an estimated 3-year survival of 18%. Survival may have been improved with earlier stage disease, but survival was not significantly improved with optimal surgical cytoreduction in patients with advanced disease. Four patients required dose reductions for myelosuppression and there was one treatment related death. Toxicity was comparable to other combination chemotherapy regimens. EPA has modest therapeutic activity in ovarian and fallopian tube MMT.

AB - Eleven patients with ovarian (9) or fallopian tube (2) mixed müllerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and doxorubicin. Responses were observed in three (60%) of five evaluable patients with two complete (40%) and one partial (20%) response. Median survival time was 17 months with an estimated 3-year survival of 18%. Survival may have been improved with earlier stage disease, but survival was not significantly improved with optimal surgical cytoreduction in patients with advanced disease. Four patients required dose reductions for myelosuppression and there was one treatment related death. Toxicity was comparable to other combination chemotherapy regimens. EPA has modest therapeutic activity in ovarian and fallopian tube MMT.

UR - http://www.scopus.com/inward/record.url?scp=0029941560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029941560&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.0148

DO - 10.1006/gyno.1996.0148

M3 - Article

C2 - 8641607

AN - SCOPUS:0029941560

SN - 0090-8258

VL - 61

SP - 309

EP - 314

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 3

ER -

Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this